for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Collegium Pharmaceutical Inc

COLL.OQ

Latest Trade

18.96USD

Change

-0.25(-1.30%)

Volume

35,358

Today's Range

18.75

 - 

19.21

52 Week Range

10.03

 - 

19.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Collegium Pharmaceutical Reports Q3 Loss Per Share Of $0.18

Nov 6 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.18.Q3 EARNINGS PER SHARE ESTIMATE $-0.15 -- REFINITIV IBES DATA.CASH INCREASED BY $5.1 MILLION, TO $153.8 MILLION AS OF SEPTEMBER 30, 2019.XTAMPZA ER NET PRODUCT REVENUES WERE $26.5 MILLION IN Q3 OF 2019, A 56% INCREASE OVER Q3 OF 2018.

Collegium Pharmaceutical Files For Mixed Shelf Offering Of Up to $300 Mln

Oct 25 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM PHARMACEUTICAL INC - FILES FOR MIXED SHELF OFFERING OF UPTO $300 MILLION.

Collegium Pharmaceutical Q2 Loss Per Share $0.14

Aug 7 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.14.Q2 EARNINGS PER SHARE ESTIMATE $-0.19 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS INCREASED TO $148.7 MILLION AS OF JUNE 30, 2019, FROM $134.9 MILLION AS OF MARCH 31, 2019.

Collegium Reports Q1 Loss Per Share $0.29

May 8 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.29.Q1 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA.QTRLY TOTAL NET PRODUCT REVENUES WERE $74.5 MILLION COMPARED TO $63.7 MILLION.

Collegium Reports Fourth-Quarter And Full-Year 2018 Financial Results

Feb 27 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.27.Q4 EARNINGS PER SHARE ESTIMATE $-0.35 -- REFINITIV IBES DATA.Q4 REVENUE $73.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $73.9 MILLION.

Collegium Says Nucynta Franchise Revenue Expected In Range Of $200 Mln To $210 Mln In 2019

Jan 7 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM PROVIDES FULL-YEAR 2019 FINANCIAL GUIDANCE.COLLEGIUM PHARMACEUTICAL INC - XTAMPZA ER REVENUE EXPECTED IN RANGE OF $95 MILLION TO $105 MILLION IN 2019.COLLEGIUM PHARMACEUTICAL INC - NUCYNTA FRANCHISE REVENUE EXPECTED IN RANGE OF $200 MILLION TO $210 MILLION IN 2019.COLLEGIUM PHARMACEUTICAL INC - TOTAL OPERATING EXPENSES EXPECTED IN RANGE OF $125 MILLION TO $135 MILLION IN 2019.

Collegium Pharmaceutical Says $135.0 Mln Guaranteed Minimum Annual Royalty Has Been Eliminated

Nov 8 (Reuters) - Assertio Therapeutics Inc <ASRT.O>::COLLEGIUM PHARMACEUTICAL - ENTERED INTO AMENDMENT TO THAT CERTAIN COMMERCIALIZATION AGREEMENT, DATED DECEMBER 4, 2017.COLLEGIUM PHARMACEUTICAL INC - PURSUANT TO AMENDMENT, $135.0 MILLION GUARANTEED MINIMUM ANNUAL ROYALTY HAS BEEN ELIMINATED.COLLEGIUM PHARMACEUTICAL INC - PURSUANT TO AMENDMENT, ROYALTY STRUCTURE FOR PERIOD BETWEEN JANUARY 1, 2019 AND DECEMBER 31, 2021 HAS BEEN REVISED.COLLEGIUM PHARMACEUTICAL INC - AMENDMENT DOES NOT MODIFY ROYALTIES PAYABLE ON SALES OF PRODUCTS ON AND AFTER JANUARY 1, 2022.

Collegium Pharmaceutical Q3 Loss Per Share $0.50

Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM REPORTS THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.34 -- THOMSON REUTERS I/B/E/S.NET PRODUCT REVENUES WERE $70.2 MILLION FOR Q3.

Collegium Pharmaceutical Q2 Loss Per Share $0.40

Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.40.Q2 REVENUE $73.1 MILLION VERSUS I/B/E/S VIEW $72.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.EXPECTS TO FINISH YEAR WITH AT LEAST $135.0 MILLION IN CASH.

Collegium Announces CEO Succession

June 4 (Reuters) - Collegium Pharmaceutical Inc <COLL.O>::COLLEGIUM ANNOUNCES CEO SUCCESSION.COLLEGIUM ANNOUNCES CEO SUCCESSION.COLLEGIUM PHARMACEUTICAL INC - MICHAEL HEFFERNAN CONTINUES TO SERVE AS CHAIRMAN OF BOARD.COLLEGIUM PHARMACEUTICAL INC - JOSEPH CIAFFONI PROMOTED TO CEO AND APPOINTED TO BOARD.COLLEGIUM PHARMACEUTICAL - CIAFFONI WILL SUCCEED HEFFERNAN AS CEO; HEFFERNAN WILL STEP DOWN AS CEO ON JUNE 30.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up